160549-10-0

Basic information

• Product Name: 2,3,5-tri-O-benzyl-D-arabinofuranose
• Synonyms: 2,3,5-Tris-O-(phenylmethyl)-D-arabinofuranose
• CAS NO: 160549-10-0
• Molecular Formula: C₂₆H₂₈O₅
• Molecular Weight: 420.49752
• Mol File: 160549-10-0.mol

Chemical Properties

• Boiling Point: 570.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.95±0.70(Predicted)
• CAS DataBase Reference: 2,3,5-tri-O-benzyl-D-arabinofuranose(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,5-tri-O-benzyl-D-arabinofuranose(160549-10-0)
• EPA Substance Registry System: 2,3,5-tri-O-benzyl-D-arabinofuranose(160549-10-0)

Safety Data

• Hazardous Substances Data: 160549-10-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3,5-tri-O-benzyl-D-arabinofuranose is used as an intermediate in the synthesis of complex carbohydrate structures and bioactive molecules. Its unique structural features make it a valuable building block for the development of novel pharmaceutical compounds, particularly those targeting carbohydrate-binding proteins or enzymes.
Used in Chemical Synthesis:
In the field of organic chemistry, 2,3,5-tri-O-benzyl-D-arabinofuranose serves as a versatile starting material for the synthesis of various derivatives and analogs. The benzyl protecting groups can be selectively removed or modified, allowing for the introduction of a wide range of functional groups and the creation of diverse chemical libraries.
Used in Research and Development:
This modified sugar is also utilized in academic and industrial research settings to study the role of carbohydrates in biological processes and to develop new methods for carbohydrate synthesis and modification. Its unique properties make it an attractive candidate for exploring the structure-activity relationships of carbohydrate-based compounds and for investigating their interactions with biological targets.
Used in the Synthesis of Phosphono Analogs:
Specifically, 2,3,5-tri-O-benzyl-D-arabinofuranose is used as an intermediate in the synthesis of the phosphono analog of N-acetyl-α-D-mannosamine 1-phosphate from D-arabinose. This phosphono analog has potential applications in the development of antiviral and antibacterial agents, as it may serve as a substrate or inhibitor for key enzymes involved in the biosynthesis of bacterial and viral cell walls.

Upstream product

• 1402833-58-2 S-acetyl-2,3,5-tris-O-(benzyl)-1-thio-β-D-arabinofuranose 
• 62255-44-1 1-O-acetyl-2,3,5-tris-O-(benzyl)-α, β-D-arabinofuranose 
• 10323-20-3 D-Arabinose 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 79083-42-4 methyl D-arabinofuranoside 
• 532-20-7 D-arabinofuranose 
• 155931-84-3 (2S,3R,4R)-2,3,5-tri-O-benzyl-4-O-formyl-pentanal 
• 201409-24-7 prop-2-enyl-2',3',5'-tri-O-benzyl-α/β-D-arabinofuranoside 
• 89824-86-2 (2R,3R,4S)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-5-methoxytetrahydrofuran 

Downstream Products

• 4645-59-4 4-O-Benzoyl-2,3,5-tri-O-benzyl-D-arabinose-diaethyldithioacetal 
• 101916-93-2 (Z)-(4R,5R,6R)-4,5,7-Tris-benzyloxy-6-hydroxy-hept-2-enoic acid tert-butyl ester 
• 101916-92-1 (E)-(4R,5R,6R)-4,5,7-Tris-benzyloxy-6-hydroxy-hept-2-enoic acid tert-butyl ester 
• 221103-29-3 (E)-(4R,5R,6R)-4,5,7-Tris-benzyloxy-6-hydroxy-hept-2-enoic acid tert-butyl ester 
• 115649-72-4 1,2-deoxy-4,5,7-tri-O-benzyl-D-manno-1-heptenitol 
• 93125-77-0 (2R,3R,4R,5S)-1,3,4-tris(benzyloxy)hept-6-ene-2,5-diol 
• 134307-34-9 2,3,5-tri-O-benzyl-1-(benzylamino)-1-deoxy-D-arabitol 
• 151593-17-8 N-benzyl-2,3,5-tri-O-benzyl-D-arabinofuranosylamine 
• 129926-94-9 2-(2',3',5'-tri-O-benzyl-β-D-arabinofuranosyl)-2-naphthol 
• 201409-24-7 prop-2-enyl-2',3',5'-tri-O-benzyl-α/β-D-arabinofuranoside 
• 404377-25-9 methyl 4,5,7-tri-O-benzyl-2-deoxy-D-gluco-hept-2-ulosonate diethyldithioacetal 
• 885669-86-3 2,3,5-tri-O-benzyl-4-O-pivaloyl-D-arabinononitrile 
• 885669-88-5 (5S,6R,7R)-6,7-dibenzyloxy-5-benzyloxymethyl-4-azaspiro[2.4]heptane 
• 885669-87-4 (2R,3R,4R)-4-(1-Amino-cyclopropyl)-1,3,4-tris-benzyloxy-butan-2-ol 

Relevant articles and documents

Small structure tree alkali compound and its preparation method and application

The invention relates to a Broussonetia kazinoki alkaline compound. Structure of the compound is shown as a formula (1). The invention further provides a preparation method of the compound, a glycosidase inhibitor by using the compound or the compound prepared by the method as an active ingredient and application of the compound or the compound, prepared by the method, serving as an active ingredient in preparing drug. The Broussonetia kazinoki alkaline compound has high glycosidase inhibiting activity and potential medicinal value.

Small structure tree alkali compound and its preparation method and application

The invention relates to a Broussonetia kazinoki alkaline compound. Structure of the compound is shown as a formula (1). The invention further provides a preparation method of the compound, a glycosidase inhibitor by using the compound or the compound prepared by the method as an active ingredient and application of the compound or the compound, prepared by the method, serving as an active ingredient in preparing drug. The Broussonetia kazinoki alkaline compound has high glycosidase inhibiting activity and potential medicinal value.

Chemical Synthesis of Ketopentose-5-phosphates

A chemical synthesis of ketopentose-5-phosphates that are involved in the pentose phosphate pathway has been developed. The ketopentose phosphates, d-ribulose-5-phosphate and d-xylulose-5-phosphate, were prepared in five steps starting from known intermed

Polyhydroxylated pyrrolidine compound as well as preparation method and application thereof

The invention relates to the field of glycosidase inhibitors and particularly relates to a polyhydroxylated pyrrolidine compound as well as a preparation method and application thereof. The structure of the polyhydroxylated pyrrolidine compound is as shown in formula (I). The polyhydroxylated pyrrolidine compound has high glycosidase inhibition activity and has a potential medicinal value. The formula is as shown in description.

List fluoro Radicamine compounds and their use and preparation method

The invention discloses a mono-fluorinated Radicamine compound which has a structure as shown in a formula (1), and further provides a preparation method for the mono-fluorinated Radicamine compound with the structure as shown in the formula (1) and an application of the mono-fluorinated Radicamine compound or the mono-fluorinated Radicamine compound prepared with the method to preparation of drugs for preventing and/or treating diabetes, drugs for preventing and/or treating Gaucher's diseases, drugs for preventing and/or treating tumors or antiviral drugs. The mono-fluorinated Radicamine compound provided by the invention is good in glycosidase inhibition activity.

β-D-Arabinosyl 1- C -sulfonic acid

A short synthetic route to β,D-arabinofuranosyl 1-C-sulfonic acid (7), a possible biomimetic for the arabinofuranosyl anomeric phosphate, is described. The furanosyl 1-C-sulfonate was prepared by buffered dimethyldioxirane oxidation of an S-acetyl-1-thio-

Stereoselective synthesis of β-arabino glycosyl sulfones as potential inhibitors of mycobacterial cell wall biosynthesis

A series of β-arabino glycosyl sulfones with varying alkyl chain lengths were synthesised in a stereoselective fashion as putative mimics of decaprenolphosphoarabinose (DPA), and as potential inhibitors of mycobacterial cell wall biosynthesis. Biological

NEW PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME

The invention provides new anticancer compounds of formula (1) such as defined in the present description. The invention also provides pharmaceutical compositions to be used in human or veterinary medicine, comprising at least one compound of formula (1). The present invention further relates to a compound of formula (1) such as defined in the present description, for use as a drug. The invention further relates to the use of a compound of formula (1) for manufacturing a human or animal anticancer pharmaceutical composition.

Synthesis of chiral carbohydrate ionic liquids

Chiral room temperature ionic liquids, containing a carbohydrate moiety linked at the anomeric centre to an N-methylimidazolium group have been synthesised. The ionic liquids were prepared in a concise manner and provided ready access to both the D- and L

Stereoselective synthesis of a ketohexofuranose from an aldohexopyranose by a [6+1-1] strategy

Ozonolysis of 2-acetoxymethyl-1,5-anhydro-3,4,6-tri-O-benzyl-2-deoxy-D- arabino-hex-1-enitol gave 1-O-acetyl-3,4,6-tri-O-benzyl-4-O-formyl-D-arabino- hex-2-ulose (5). Subsequent hydrolysis and acetylation of 5 provided 1,2-di-O-acetyl-3,4,6-tri-O-benzyl-D